Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Amy E. DeZern, Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J. Swinnen, Philip H. Imus, Nina D. Wagner-Johnston, Richard F. Ambinder, Mark Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J. Fuchs, Richard J. Jones, Robert A. Brodsky

Blood (2023) 141 (25): 3031–3038.

https://doi.org/10.1182/blood.2023020435

Published: 2023

Includes: Supplemental data

Journal Articles

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik

Blood (2022) 139 (4): 608–623.

https://doi.org/10.1182/blood.2021013054

Published: 2022

Includes: Supplemental data

Journal Articles

Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction

Yvette L. Kasamon, Ephraim J. Fuchs, MD, Marianna Zahurak, Gary L. Rosner, Heather J. Symons, Javier Bolaños-Meade, Richard J. Jones

Blood (2016) 128 (22): 831.

https://doi.org/10.1182/blood.V128.22.831.831

Published: 2016

Journal Articles

Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome

Philip H Imus, MD, August R Dietrich, MD, Amanda Blackford, ScM, Robert A. Brodsky, MD, Heather J. Symons, Kenneth Cooke, MD, Richard J Jones, MD, Javier Bolaños-Meade, MD

Blood (2016) 128 (22): 2252.

https://doi.org/10.1182/blood.V128.22.2252.2252

Published: 2016

Journal Articles

Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA)

Amy E. DeZern, MD MHS, Donna Dorr, RN, MSN, AOCN, Leo Luznik, MD, Javier Bolanos-Meade, MD, Christopher Gamper, MD PhD, Heather J. Symons, MD MHS, Kenneth R. Cooke, MD, Richard J. Jones, Sr., MD, Robert A. Brodsky, MD

Blood (2015) 126 (23): 2031.

https://doi.org/10.1182/blood.V126.23.2031.2031

Published: 2015

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Shannon R. McCurdy, Christopher G. Kanakry, Yvette L. Kasamon, MD, Javier Bolanos Meade, MD, Hua-Ling Tsai, Margaret M. Showel, Jennifer A. Kanakry, Heather J. Symons, MD MHS, Gary L. Rosner, Sc.D, Ephraim J. Fuchs, Richard J. Jones, Leo Luznik, MD

Blood (2014) 124 (21): 730.

https://doi.org/10.1182/blood.V124.21.730.730

Published: 2014

Journal Articles

Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol

Blood (2013) 122 (21): 700.

https://doi.org/10.1182/blood.V122.21.700.700

Published: 2013

Journal Articles

The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)

Amer M. Zeidan, MD, Patrick Forde, MD, Heather J. Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, B. Douglas Smith, MD, Ephraim J. Fuchs, Leo Luznik, Richard J. Jones, Javier Bolaños-Meade, MD

Blood (2013) 122 (21): 4629.

https://doi.org/10.1182/blood.V122.21.4629.4629

Published: 2013

Journal Articles

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice M. Davis-Sproul, Nilanjan Ghosh, Heather J. Symons, MD, MHS, Javier Bolaños-Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

Blood (2012) 120 (21): 3084.

https://doi.org/10.1182/blood.V120.21.3084.3084

Published: 2012

Journal Articles

Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol

Blood (2012) 120 (21): 738.

https://doi.org/10.1182/blood.V120.21.738.738

Published: 2012

Journal Articles

Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation

Nirali N Shah, MD, Michael J. Borowitz, MD, PhD, Nancy Robey, PA, Christopher Gamper, MD, PhD, Heather J. Symons, MD, MHS, David Loeb, MD, PhD, Alan S Wayne, MD, Allen R. Chen, MD, PhD, MHS

Blood (2012) 120 (21): 4205.

https://doi.org/10.1182/blood.V120.21.4205.4205

Published: 2012

Journal Articles

Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation

Nirali N Shah, MD, Michael J. Borowitz, MD, PhD, Seth M. Steinberg, PhD, Mary Lefell, PhD, Nancy Robey, PA, Christopher Gamper, MD, PhD, Heather J. Symons, MD, MHS, David Loeb, MD, PhD, Alan S Wayne, MD, Allen R. Chen, MD, PhD, MHS

Blood (2012) 120 (21): 4206.

https://doi.org/10.1182/blood.V120.21.4206.4206

Published: 2012

Journal Articles

Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol

Blood (2011) 118 (21): 487.

https://doi.org/10.1182/blood.V118.21.487.487

Published: 2011

Journal Articles

Significance of Missing Inhibitory KIR Ligands in Nonmyeloablative, HLA-Haploidentical (Haplo) BMT with Posttransplantation High-Dose Cyclophosphamide (PT/Cy)

Yvette L. Kasamon, Leo Luznik, M. Sue Leffell, Hua-ling Tsai, Heather J. Symons, Javier Bolaños-Meade, Gary Rosner, Lawrence E. Morris, Pamela A. Crilley, Richard J. Jones, Ephraim J. Fuchs

Blood (2011) 118 (21): 840.

https://doi.org/10.1182/blood.V118.21.840.840

Published: 2011

Journal Articles

Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide

Heather J. Symons, Chimene Kesserwan, MD, Ferdynand Kos, PhD, Christopher J. Thoburn, MsC, Ashley T. Munchel, MD, Wendy Ying, BA, Leo Luznik, Hyam I. Levitsky, MD, Richard J. Jones, MD, Allan D. Hess, PhD, Ephraim J. Fuchs

Blood (2011) 118 (21): 1009.

https://doi.org/10.1182/blood.V118.21.1009.1009

Published: 2011

Journal Articles

Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,

Heather J. Symons, Allen R. Chen, MD, PhD, MHS, Leo Luznik, Yvette L. Kasamon, Javier Bolanos Meade, MD, Richard J. Jones, Ephraim J. Fuchs

Blood (2011) 118 (21): 4151.

https://doi.org/10.1182/blood.V118.21.4151.4151

Published: 2011

Journal Articles

Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy).

Heather J. Symons, MD, Leo Luznik, MD, Michele Phelps, Angelita Crawford, Katherine McIntyre, M. Yair Levy, MD, Richard J. Jones, MD, Ephraim J. Fuchs, MD

Blood (2006) 108 (11): 2859.

https://doi.org/10.1182/blood.V108.11.2859.2859

Published: 2006

Journal Articles

Impact of Killer Immunoglobulin Receptor (KIR) Ligand Incompatibility in Nonmyeloablative Bone Marrow Transplantation (BMT) from Haploidentical Donors.

Heather J. Symons, MD, M. Sue Leffell, PhD, Nancy D. Rossiter, Elizabeth Sugar, PhD, Leo Luznik, MD, Michele Phelps, Angelita Crawford, M. Yair Levy, MD, Richard J. Jones, MD, Ephraim J. Fuchs, MD

Blood (2006) 108 (11): 604.

https://doi.org/10.1182/blood.V108.11.604.604

Published: 2006

Journal Articles

Clinical Tumor Responses Despite Graft Rejection after Nonmyeloablative Conditioning and Transplantation of Partially HLA-Mismatched (Haploidentical) Bone Marrow.

Moshe Y. Levy, MD, Heather J. Symons, MD, Ephraim J. Fuchs

Blood (2005) 106 (11): 2897.

https://doi.org/10.1182/blood.V106.11.2897.2897

Published: 2005

NARROW

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction

Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome

Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA)

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol

The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol

Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation

Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation

Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol

Significance of Missing Inhibitory KIR Ligands in Nonmyeloablative, HLA-Haploidentical (Haplo) BMT with Posttransplantation High-Dose Cyclophosphamide (PT/Cy)

Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide

Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,

Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy).

Impact of Killer Immunoglobulin Receptor (KIR) Ligand Incompatibility in Nonmyeloablative Bone Marrow Transplantation (BMT) from Haploidentical Donors.

Clinical Tumor Responses Despite Graft Rejection after Nonmyeloablative Conditioning and Transplantation of Partially HLA-Mismatched (Haploidentical) Bone Marrow.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only